{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:03:51Z","timestamp":1792015431380,"version":"4.4.0"},"reference-count":119,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["iubmb.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biotech and App Biochem"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Escherichia coli<\/jats:italic> has shouldered a massive workload with the discovery of recombinant DNA technology. A new era began in the biopharmaceutical industry with the production of insulin, the first recombinant protein, in <jats:italic>E. coli<\/jats:italic> and its use in treating diabetes. After insulin, many biopharmaceuticals produced from <jats:italic>E. coli<\/jats:italic> have been approved by the US Food and Drug Administration and the European Medicines Agency to treat various human diseases. Although <jats:italic>E. coli<\/jats:italic> has some disadvantages, such as lack of post\u2010translational modifications and toxicity, it is an important host with advantages such as being a well\u2010known bacterium in recombinant protein production, cheap, simple production system, and high yield. This study examined biopharmaceuticals produced and approved in <jats:italic>E. coli<\/jats:italic> under the headings of peptides, hormones, enzymes, fusion proteins, antibody fragments, vaccines, and other pharmaceuticals. The topics on which these biopharmaceuticals were approved for treating human diseases, when and by which company they were produced, and their use and development in the field are included.<\/jats:p>","DOI":"10.1002\/bab.2664","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T05:19:49Z","timestamp":1725859189000},"page":"528-541","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["<i>Escherichia coli<\/i> in the production of biopharmaceuticals"],"prefix":"10.1002","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4599-6908","authenticated-orcid":false,"given":"\u0130brahim","family":"\u0130ncir","sequence":"first","affiliation":[{"name":"Kaz\u0131m Karabekir Vocational School, Department of Medical Services and Techniques, Environmental Health Program Karamano\u011flu Mehmetbey University  Karaman Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Rafet Kay\u0131\u015f Faculty of Engineering, Department of Genetics and Bioengineering Alanya Alaaddin Keykubat University  Antalya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7036343"},{"key":"e_1_2_7_3_1","article-title":"History of insulin","volume":"2","author":"Quianzon CC","year":"2012","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-0875-7_4"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.1412.12079"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2019.00420"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826068.2021.1952597"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.16984\/saufenbilder.961026"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105565"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2024.106463"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-021-01698-w"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2023.108267"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/biologics3040021"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6337396"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjm.2016.10.007"},{"key":"e_1_2_7_16_1","unstructured":"FDA.LYUMJEV (insulin lispro\u2010aabc) injection for subcutaneous or intravenous use. 2020. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761109s003lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_17_1","unstructured":"EMA.Lyumjev. 2020. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lyumjev\u2010previously\u2010liumjev. Accessed 3 Oct 2023."},{"key":"e_1_2_7_18_1","unstructured":"FDA.SOGROYA\u00ae(somapacitan\u2010beco) injection for subcutaneous use Initial U.S.2020. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761156s005lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_19_1","unstructured":"EMA.Sogroya.2021. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sogroya. Accessed 3 Oct 2023."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa049"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac513"},{"key":"e_1_2_7_22_1","unstructured":"FDA.SKYTROFA\u2122 (lonapegsomatropin\u2010tcgd) for injection for subcutaneous use.2021. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761177lbl.pdf"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-016-0437-3"},{"key":"e_1_2_7_24_1","unstructured":"FDA. INTRON\u00ae A. 2018. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103132Orig1s5199lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_25_1","unstructured":"FDA.BESREMi (ropeginterferon alfa\u20102b\u2010njft) injection for subcutaneous use.2021. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761166s000lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4"},{"key":"e_1_2_7_27_1","article-title":"Real world experience with ropeginterferon alpha\u20102b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa\u20102a (Pegasys)","volume":"19","author":"Okikiolu J","year":"2023","journal-title":"Leuk Res Rep"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep15010018"},{"key":"e_1_2_7_29_1","unstructured":"EMA.Forsteo.2003. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/forsteo. Accessed 3 Oct 2023."},{"key":"e_1_2_7_30_1","unstructured":"EMA.Sondelbay.2022. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sondelbay\u20100. Accessed 3 Oct 2023."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0438-2"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-01010"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01800-y"},{"key":"e_1_2_7_34_1","unstructured":"EMA.Natpar.2017. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/natpar. Accessed 3 Oct 2023."},{"key":"e_1_2_7_35_1","first-page":"115","article-title":"Hormones, blood products, and therapeutic enzymes","volume":"171","author":"Silva AC","year":"2020","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42335"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab019"},{"key":"e_1_2_7_38_1","unstructured":"FDA.VORAXAZE\u00ae(glucarpidase) for injection for intravenous use.2012. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125327lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_39_1","unstructured":"EMA.Voraxaze.2022. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/voraxaze\u20100. Accessed 3 Oct 2023."},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-022-03276-5"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5763"},{"key":"e_1_2_7_42_1","unstructured":"FDA.PALYNZIQ (pegvaliase\u2010pqpz) injection for subcutaneous use.2018. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761079s000lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_43_1","article-title":"Use of pegvaliase in the management of phenylketonuria: case series of early experience in US clinics","volume":"28","author":"Adams D","year":"2021","journal-title":"Mol Genet Metab Rep"},{"key":"e_1_2_7_44_1","article-title":"Real\u2010world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: evidence from dispensing data","volume":"33","author":"Lah M","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"e_1_2_7_45_1","unstructured":"FDA.REVCOVI (elapegademase\u2010lvlr) injection for intramuscular use.2018. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761092s000lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01426-y"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.01.028"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179181"},{"key":"e_1_2_7_49_1","unstructured":"FDA.NATRECOR\u00ae(nesiritide) lyophilized powder for intravenous use.2001. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020920s031lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389201022666210702123934"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-820007-0.00026-X"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00904-4"},{"key":"e_1_2_7_53_1","unstructured":"EMA.Voxzogo.2021. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/voxzogo. Accessed 3 Oct 2023."},{"key":"e_1_2_7_54_1","unstructured":"FDA.VOXZOGO (vosoritide) for injection for subcutaneous use.2021. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214938s000lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31541-5"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01287-7"},{"key":"e_1_2_7_57_1","unstructured":"EMA.Oxervate.2017. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/oxervate. Accessed 3 Oct 2023."},{"key":"e_1_2_7_58_1","unstructured":"FDA.OXERVATE\u2122 (cenegermin\u2010bkbj) ophthalmic solution for topical ophthalmic use.2018. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761202s000lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158414221134598"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101584"},{"key":"e_1_2_7_61_1","unstructured":"EMA.Idefirix.2020. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/idefirix. Accessed 3 Oct 2023."},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11244"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16828"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.11.064"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61030-6"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00435-2"},{"key":"e_1_2_7_67_1","unstructured":"EMA.Strangvac.2021. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/strangvac. Accessed 3 Oct 2023."},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.05.046"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2011.08.022"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08869-9"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.036"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-022-01792-7"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.092"},{"key":"e_1_2_7_74_1","unstructured":"FDA.TRUMENBA\u00ae(Meningococcal Group B Vaccine) Suspension for intramuscular injection.2014. Available from:https:\/\/www.fda.gov\/media\/89936\/download. Accessed 3 Oct 2023."},{"key":"e_1_2_7_75_1","unstructured":"EMA.Trumenba.2017. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trumenba. Accessed 3 Oct 2023."},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.053"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2041359"},{"key":"e_1_2_7_78_1","unstructured":"EMA.Bexsero.2013. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bexsero. Accessed 3 Oct 2023."},{"key":"e_1_2_7_79_1","unstructured":"FDA.BEXSERO (Meningococcal Group B Vaccine) suspension for intramuscular injection.2015. Available from:https:\/\/www.fda.gov\/media\/90996\/download. Accessed 3 Oct 2023."},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.071"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2222015"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206433"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-019-00606-9"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(91)90262-5"},{"key":"e_1_2_7_85_1","unstructured":"EMA.Leucogen.2009. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/leucogen. Accessed 3 Oct 2023."},{"key":"e_1_2_7_86_1","unstructured":"EMA.Letifend.2016. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/letifend.Accessed 3 Oct 2023."},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00312-2"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2157"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1177\/019262339902700507"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-017-0083-9"},{"key":"e_1_2_7_91_1","unstructured":"FDA.BYOOVIZ (ranibizumab\u2010nuna) injection for intravitreal use.2021. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761202s000lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_92_1","unstructured":"FDA.SUSVIMO\u2122 (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant.2021. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761197s000lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1309\/Y6LPC0LR726L9DX9"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-019-00221-2"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3102"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-023-02115-0"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20225"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.24555"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.21024"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1939"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0487"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.309319"},{"key":"e_1_2_7_103_1","first-page":"1590","article-title":"Targeting von Willebrand factor\u2010mediated inflammation","volume":"37","author":"Drakeford C","year":"2017","journal-title":"Am Heart Assoc"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-317859"},{"key":"e_1_2_7_105_1","unstructured":"EMA. Cablivi.2018. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cablivi.Accessed 3 Oct 2023."},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042303"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2111748"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901778"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12734"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100047"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070971"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2764"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2008.0579"},{"key":"e_1_2_7_114_1","first-page":"2837","article-title":"A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule\u2010specific single\u2010chain antibody fragment has potent and selective antitumor activity","volume":"9","author":"Di Paolo C","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2011.03.009"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.04.017"},{"key":"e_1_2_7_117_1","unstructured":"FDA.STIMUFEND\u00ae(pegfilgrastim\u2010fpgk) injection for subcutaneous use.2022. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761173s000lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_118_1","unstructured":"EMA.Stimufend. 2022. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stimufend. Accessed 3 Oct 2023."},{"key":"e_1_2_7_119_1","unstructured":"FDA.Kineret\u00ae(anakinra) for injection for subcutaneous use. 2001. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103950s5136lbl.pdf. Accessed 3 Oct 2023."},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2329"}],"container-title":["Biotechnology and Applied Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iubmb.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bab.2664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T23:30:17Z","timestamp":1744068617000},"score":1,"resource":{"primary":{"URL":"https:\/\/iubmb.onlinelibrary.wiley.com\/doi\/10.1002\/bab.2664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/bab.2664"],"URL":"https:\/\/doi.org\/10.1002\/bab.2664","archive":["Portico"],"relation":{},"ISSN":["0885-4513","1470-8744"],"issn-type":[{"value":"0885-4513","type":"print"},{"value":"1470-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,8]]},"assertion":[{"value":"2024-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}